As long-term smokers undergo computed tomography (CT) to screen for lung cancer, cases of interstitial lung disease are being discovered incidentally. This article explains how to distinguish among the most common forms of interstitial lung disease in this situation and the role of primary care physicians in managing them.
P
rimary care physicians are playing a bigger role in evaluating the incidental fi nding of interstitial lung diseases since the recent publication of guidelines recommending computed tomography (CT) to screen for lung cancer.
In August 2011, the National Cancer Institute published its fi ndings from the National Lung Screening Trial, which demonstrated a 20% reduction in mortality from lung cancer in patients at high risk screened with lowdose CT. 1 Based on these results, the American Cancer Society, the American College of Chest Physicians, the American Society of Clinical Oncology, and the National Comprehensive Cancer Network recommended annual screening for lung cancer with low-dose CT in adults ages 55 to 74 who have a 30-packyear smoking history and who currently smoke or have quit within the past 15 years. 2 In December 2013, the US Preventive Services Task Force published similar guidelines but increased the age range to include high-risk patients ages 55 to 80. 3 Bach et al 4 estimated that, in 2010 in the United States, 8.6 million people met the criteria used in the National Lung Screening Trial for low-dose CT screening. These are the same criteria as in the multisociety recommendations cited above. 2 With such large numbers of patients eligible for CT screening, internists and other primary care physicians are undoubtedly encountering the incidental discovery of nonmalignant pulmonary diseases such as interstitial lung disease.
This article reviews the radiographic characteristics of the most common interstitial 
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lung diseases the internist may encounter on screening CT in long-term smokers.
Referral to a specialist has been associated with lower rates of morbidity and death, 5 and a diagnosis of interstitial lung disease should be confi rmed by a pulmonologist and a radiologist specializing in differentiating the subtypes. But the primary care physician now plays a critical role in recognizing the need for further evaluation.
■ HOW COMMON IS INTERSTITIAL LUNG DISEASE IN SMOKERS?
Several studies have published data on the prevalence of interstitial lung disease in patients undergoing low-dose CT for lung cancer screening.
A trial at Mayo Clinic in current and former smokers identifi ed "diffuse lung disease" in 9 (0.9%) of 1,049 participants. 
Respiratory bronchiolitis

FIGURE 2.
In a 40-year-old woman with a 15-pack-year smoking history with respiratory bronchiolitis-interstitial lung disease, high-resolution CT obtained through the upper lungs at initial diagnosis (left) shows diffuse faint centrilobular ground-glass nodules (red arrows). Highresolution CT 1 year after smoking cessation (right) shows complete resolution of the centrilobular nodules.
Respiratory bronchiolitis-interstitial lung disease
Desquamative interstitial pneumonia Desquamative interstitial pneumonia and emphysema
A trial in Ireland identifi ed idiopathic pulmonary fi brosis in 6 (1.3%) of 449 current smokers who underwent low-dose CT screening for lung cancer. 7 Sverzellati et al 8 evaluated 692 participants in the Multicentric Italian Lung Detection CT screening study and reported a respiratory bronchiolitis pattern in 109 (15.7%), a usual interstitial pneumonia pattern in 2 (0.3%), and other patterns of chronic interstitial pneumonia in 26 (3.8%).
The National Lung Screening Trial reported that the frequency of "clinically signifi cant" incidental fi ndings (including pulmonary fi brosis) in all participants was 7.5%. 1 A retrospective analysis of 884 participants at a single site in this trial identifi ed interstitial lung abnormalities in 86 participants (9.7%). 9 These abnormalities were further categorized as nonfi brotic in 52 (5.9%) of 884, fi brotic in 19 (2.1%) of 884, and mixed fi brotic and nonfi brotic in 15 (1.7%) of 884.
Follow-up CT at 2 years in this trial demonstrated improvement in 50% and progression in 11% of patients who had nonfi brotic abnormalities, while fi brotic abnormalities improved in no cases and progressed in 37%.
Interstitial lung abnormalities were more common in those who currently smoked and in those with more pack-years of cigarette smoking. 9 In sum, these trials suggest that low-dose CT screening for lung cancer can detect the most common forms of interstitial lung disease in this at-risk population and can characterize them as fi brotic or nonfi brotic, a distinction important for prognosis and subsequent management.
■ NONFIBROTIC VS FIBROTIC DISEASE
It is important to distinguish between nonfibrotic and fi brotic interstitial lung disease, as fi brotic disease carries a worse prognosis and is treated differently.
Features of nonfi brotic interstitial lung disease:
• Ground-glass opacities • Nodules • Mosaic attenuation or consolidation.
The primary care physician now plays a critical role in recognizing the need for further evaluation 
■ NONFIBROTIC INTERSTITIAL LUNG DISEASES
Given the strong likelihood that a patient undergoing screening CT is either a current or former smoker, physicians may encounter, in addition to emphysema and lung cancer, the following smoking-related interstitial lung diseases, which are primarily nonfi brotic and which frequently coexist ( Table 1) 
Respiratory bronchiolitis
Respiratory bronchiolitis occurs mostly in smokers and does not necessarily lead to respiratory symptoms in all patients. 10 It cannot always be identifi ed radiographically but occasionally appears as predominantly upper-lobe, patchy ground-glass opacities or ill-defi ned centrilobular nodules without evidence of fibrosis (Figure 1) .
Respiratory bronchiolitisinterstitial lung disease
In rare cases, respiratory bronchiolitis leads to peribronchial fi brosis invading the alveolar walls, which is then classifi ed as respiratory bronchiolitis-interstitial lung disease. 11 The CT fi ndings in respiratory bronchiolitisinterstitial lung disease are upper-lobe-predominant centrilobular ground-glass nodules, patchy ground-glass opacities, and bronchial wall thickening (Figure 2) . 10 Occasionally, mild reticulation is noted without honey- The only successful therapy for respiratory bronchiolitis and respiratory bronchiolitisinterstitial lung disease is smoking cessation. Finding either of these diseases should prompt aggressive counseling by the internist and consideration of referral to a specialist in interstitial lung disease.
Desquamative interstitial pneumonia
Although pathologically different from respiratory bronchiolitis-interstitial lung disease, desquamative interstitial pneumonia has a similar clinical and radiographic presentation. Because their features signifi cantly overlap, they are considered a pathomorphologic continuum, representing degrees of severity of the same disease process caused by prolonged tobacco inhalation. 10, 13 Widespread ground-glass opacities are the predominant CT fi nding. These are bilateral and symmetric in distribution in 86%, basal and peripheral in 60%, patchy in 20%, and diffuse in 20% (Figure 3) . 14 Other frequent fi ndings are mild reticulation with traction bronchiectasis and coexistent emphysema (Figure 4) . 15 The small peripheral cystic spaces noted in this disease most likely represent dilated bronchioles and alveolar ducts rather than honeycombing. 16 No additional treatment beyond elimination of smoking has been proven effective for desquamative interstitial pneumonia, and patients who manage to quit smoking generally have a favorable prognosis.
17,18
Pulmonary Langerhans cell histiocytosis The combination of upper-lobe-predominant cysts and nodules in a young heavy smoker are diagnostic of pulmonary Langerhans cell histiocytosis. The cysts are bizarrely shaped, thin-or thick-walled, and nonuniform in size ( Figure 5) . The irregular cavitary nodules are centrilobular. The disease characteristically spares the costophrenic angles.
Spontaneous pneumothorax is the initial clinical presentation in 15% of patients. 16 In the early stages of the disease (nodulepredominant disease without cysts), infection and metastatic disease need to be excluded (Figure 6 ). In the later stages, the cysts become coalescent, making the distinction between this disease and "burned-out" lymphangioleiomyomatosis or severe emphysema extremely diffi cult (Figure 7) . 17 Smoking cessation and corticosteroids are the mainstay of medical therapy for pulmonary Langerhans cell histiocytosis, and about 50% of patients who quit smoking and receive corticosteroids demonstrate partial or complete clearing of the radiographic abnormalities and symptoms (Figure 8 ).
Pulmonary Langerhans cell histiocytosis Pulmonary Langerhans cell histiocytosis
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■ FIBROTIC INTERSTITIAL LUNG DISEASES
If CT identifi es a diffuse fi brotic pattern, the two most common possibilities ( Table 2) are:
• Nonspecifi c interstitial pneumonia • Usual interstitial pneumonia. As noted above, these carry a worse prognosis than the nonfi brotic interstitial lung diseases.
Nonspecifi c interstitial pneumonia
While most frequently idiopathic, the nonspecifi c interstitial pneumonia pattern can often be seen in connective tissue diseases. It has also been associated with chronic hypersensitivity pneumonitis, drug toxicity, and slowly resolving diffuse alveolar damage. 19 Although it is not the only pathologic pattern in interstitial lung disease associated with connective tissue disease, it is the most common pattern in systemic sclerosis, systemic lupus erythematosus, dermatomyositis-polymyositis, and mixed connective tissue disease. 20 The parenchymal changes are typically subpleural and symmetric in distribution (Figure 9) . In about one-third of cases, there is a peribronchovascular distribution of the abnormalities (Figure 10) .
Ground-glass opacities are the dominant imaging fi ndings, seen in 80% of cases. 18 In advanced disease (also referred to as fi brotic nonspecifi c interstitial pneumonia), patients have accompanying fi ne or coarse reticular opacities, traction bronchiectasis, and consolidation (Figure 11) . Honeycombing is seen in 1% to 5% of patients. 21 The most specifi c sign of nonspecifi c interstitial pneumonia is sparing of the immediate subpleural lung, apparent in 30% to 50% of patients (Figure 12) . 22 Subpleural sparing with a peribronchovascular distribution of abnormalities, absence of lobular areas with decreased attenuation, and lack of honeycombing are imaging features that increase the diagnostic confi dence of nonspecifi c interstitial pneumonia ( Table 3) . 23 Clinically, compared with those who have usual interstitial pneumonia (see below), patients are younger and more of them are female. These patients also present with extrapulmonary manifestations such as joint involvement, rash, and Raynaud phenomenon. Therefore, these associated symptoms on presentation can help distinguish nonspecifi c interstitial pneumonia or usual interstitial pneumonia related to connective tissue disease from the idiopathic forms.
The fi rst step in managing nonspecifi c interstitial pneumonia is to remove all potential exposure to inhaled substances or to drugs. Although immunosuppressive therapy has never been studied in a randomized controlled trial in this disease, numerous reports suggest that patients may respond to prednisone and to steroid-sparing immunosuppressants. 
INTERSTITIAL LUNG DISEASE
In several studies, survival rates in nonspecifi c interstitial pneumonia were signifi cantly greater than in usual interstitial pneumonia independent of the treatment strategy. In long-term follow-up of patients with idiopathic nonspecifi c interstitial pneumonia treated with immunosuppressive therapy, two-thirds remained stable or improved. [25] [26] [27] Although most connective tissue diseases cause a lung pattern of nonspecifi c interstitial pneumonia, some (eg, rheumatoid arthritis) may present with a pattern of usual interstitial pneumonia. In these cases and in those of advanced fi brotic nonspecifi c interstitial pneumonia, the prognosis is worse, as the disease is less responsive to immunosuppressive therapy. 20 
Usual interstitial pneumonia
Usual interstitial pneumonia is the most severe form of lung fi brosis. Most cases are idiopathic and are termed idiopathic pulmonary fi brosis. Other causes of the usual interstitial pneumonia pattern include domestic and occupational environmental exposures, connective tissue disease, and drug toxicity. 28 An epidemiologic association between smoking and usual interstitial pneumonia is well documented. 28 Idiopathic pulmonary fi brosis typically affects men ages 50 to 70. Because its risk factors coincide with those of lung cancer, there is a high likelihood of detecting idiopathic pulmonary fi brosis early in this screening population. It has an especially poor prognosis, with a mean survival of 2 to 5 years from the time of diagnosis. 18 The distribution of disease in usual interstitial pneumonia is characteristically subpleural and basal. CT features include coarse subpleural reticulation and honeycombing combined with traction bronchiectasis or bronchiolectasis and architectural distortion (Figure 13) . 18 Honeycombing is the most specifi c and key diagnostic CT fi nding for establishing a defi nitive diagnosis of usual interstitial pneumonia. 29 However, ground-glass opacities are present in most patients, typically in the region of interstitial fi brosis, and are always less extensive than the reticulation. 30 The fi ndings demonstrate morphologic heterogeneity, with areas of fi brosis adjacent to areas of normal lung (Figure 14) .
In addition to the aforementioned imaging features, the 2011 American Thoracic Society and European Respiratory Society joint guidelines for the CT diagnosis of usual interstitial pneumonia patterns require the absence of Those with the longest delay in referral had a death rate 3.4 times higher than those with the shortest delay 
Nonspecifi c interstitial pneumonia
Nonspecifi c interstitial pneumonia
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atypical features that suggest an alternative diagnosis, including those seen in nonspecifi c interstitial pneumonia, such as an upper, midlung, or peribronchovascular distribution and extensive ground-glass attenuation. 28 Mild mediastinal lymphadenopathy (usually < 1.5 cm in the short axis) is common in usual interstitial pneumonia. 31 Because other chronic interstitial pneumonias that may resemble usual interstitial pneumonia have a more favorable course and may respond to immunosuppressive therapy, establishing an early and accurate diagnosis is of the utmost importance. 5 Additionally, the emergence of possible new therapies for idiopathic pulmonary fi brosis makes early referral to a specialist paramount in these cases. Recent studies have demonstrated signifi cant slowing of the progression of disease in idiopathic pulmonary fi brosis with both pirfenidone and nintedanib. 32, 33 ■ DIAGNOSIS AND MANAGEMENT The diagnosis of these nonfi brotic and fi brotic lung diseases is complex. In all cases in which interstitial lung disease is detected on screening CT for lung cancer, the internist should strongly consider further evaluation with dedicated high-resolution CT and early referral to a specialist (Figure 15 ).
Because smoking cessation is the only recommended treatment for nonfi brotic smoking-related interstitial lung diseases, particular emphasis on smoking cessation counseling is essential.
Referral for bronchoscopy with transbronchial lung biopsy is generally not helpful in FIGURE 12 . In a 52-year-old woman with mild dyspnea and fatigue, high-resolution CT through the lower lungs shows bilateral symmetric peripheral ground-glass opacities with sparing of the immediate subpleural lung (white arrows), the most specifi c sign of nonspecifi c interstitial pneumonia.
Nonspecifi c interstitial pneumonia FIGURE 13. In a 68-year-old man, high-resolution CT through the lower lungs shows features of usual interstitial pneumonia: bilateral subpleural reticular opacities, traction bronchiectasis (blue arrow), ground-glass opacities (red arrow), and honeycombing, seen as rows of clustered subpleural cystic air spaces (yellow arrow). FIGURE 14 . In a 67-year-old man with usual interstitial pneumonia, high-resolution CT through the lower lungs shows basal-predominant subpleural honeycombing (red arrow). Morphologic heterogeneity is seen with areas of fi brosis immediately adjacent to normal lung (white double arrow).
Usual interstitial pneumonia
the diagnosis of the interstitial lung diseases discussed in this article unless there is a need to rule out infection or neoplasm. 34 Referral for surgical lung biopsy may be indicated in some cases of suspected pulmonary Langerhans cell histiocytosis, desquamative interstitial pneumonia, nonspecifi c interstitial pneumonia, or usual interstitial pneumonia if the diagnosis is uncertain (Tables 1 and 2 ). 35 The American Thoracic Society/European Respiratory Society guidelines suggest a multidisciplinary team approach that includes a pathologist, radiologist, and clinician. 35 This approach more readily determines the correct diagnosis and relies less on invasive methods such as surgical biopsy and more on noninvasive methods such as radiology and clinical history. Overall, this will promote earlier access to appropriate therapies, clinical trial enrollment, and in more severe cases, lung transplant.
Currently, 23% of all lung transplants worldwide are performed in patients with idiopathic pulmonary fi brosis. Other forms of pulmonary fi brosis account for 3% to 4% of lung transplants performed. 36 Evidence suggests that early referral reduces rates of morbidity and death in these patients. The results of a single-center study 37 of patients with idiopathic pulmonary fi brosis demonstrated that a longer delay from the onset of symptoms to evaluation by a specialist at a tertiary care referral center was associated with a higher rate of death from this disease independent of disease severity. Those with the longest delay in referral had a multivariable-adjusted death rate 3.4 times higher than those with the shortest delay. 5, 37 In summary, with implementation of the new lung cancer screening guidelines, primary care physicians are more often encountering the incidental fi nding of interstitial lung disease in their patients. Prompt diagnosis of interstitial lung disease helps ensure that patients receive appropriate care and early consideration for clinical trials and lung transplant.
Primary care physicians play a critical role in the initial identifi cation of key characteristics of the interstitial abnormality-namely, whether the pattern is nonfi brotic or fi brotic-and in the correlation of the history and 
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physical fi ndings to expedite the diagnosis. Subsequently, ordering high-resolution CT for more detailed characterization and prompt referral to a specialist in interstitial lung disease allow for a more rapid and accurate diagnosis, specialized therapy, and supportive care. ■
